León-González, Antonio J.Acero de Mesa, NuriaMuñoz Mingarro, DoloresNavarro Zafra, InmaculadaMartín-Cordero, CarmenUniversidad San Pablo-CEU. Facultad de Farmacia. Departamento de Ciencias Farmacéuticas y de la SaludGrupo: Productos naturales (CEU-PRONAT)2024-03-212024-03-212015León-González AJ, Acero N, Muñoz-Mingarro D, Navarro I, Martín-Cordero C. Chalcones as Promising Lead Compounds on Cancer Therapy. Curr Med Chem. 2015;22(30):3407-25. doi: 10.2174/09298673226661507291148291875-533Xhttp://hdl.handle.net/10637/15666Versión en acceso abierto siguiendo política de la revistaChalcones constitute a group of phenolic compounds that command an increasing interest on cancer research. Natural chalcones are widespread through the plant kingdom. The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families. These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers. In recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties. This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chemical moiety modifications could lead them to be therapeutically useful in the treatment of cancer.application/pdfenopen accessApoptosisCancerChalconeChemopreventionFlavonoidSynthesisTubulinArtículo10.2174/0929867322666150729114829https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es